Table 2 Association between PSMD6 rs831571 and clinical features in the repaglinide cohort.

From: A variant of PSMD6 is associated with the therapeutic efficacy of oral antidiabetic drugs in Chinese type 2 diabetes patients

Parameter

 

CC

CT

TT

P value

Age(year)

 

52.12±1.49

52.52±1.30

54.29±3.98

0.7514

Gender(male/female)

 

19/15

37/13

5/2

0.1311

Dosage(mg/day)

 

2.67±0.27

2.57±0.21

1.53±0.03

0.1692

BMI(kg/m2)

Baseline

25.78±0.48

25.16±0.40

25.57±0.66

0.6694

 

24weeks

25.61±0.47

25.07±0.44

25.36±0.81

0.5446

 

48weeks

25.71±0.48

24.94±0.45

25.69±0.88

0.4215

 

Δ24weeks

–0.16±0.16

–0.07±0.20

–0.20±0.22

0.8471

 

Δ48weeks

–0.07±0.14

–0.21±0.22

0.13±0.28

0.7226

Fasting glucose(mmol/l)

Baseline

9.15±0.31

9.64±0.28

9.39±0.55

0.6672

 

24weeks

6.73±0.18

6.39±0.15

6.78±0.47

0.5416

 

48weeks

7.18±0.30

6.86±0.19

6.74±0.41

0.9194

 

Δ24weeks

–2.39±0.31

–3.30±0.28

–2.61±0.45

0.1695

 

Δ48weeks

–1.87±0.32

–2.76±0.29

–2.65±0.53

0.0371

2–h glucose(mmol/l)

Baseline

13.02±0.55

13.98±0.42

15.33±0.78

0.0175

 

24weeks

9.34±0.39

8.35±0.29

8.86±0.62

0.1742

 

48weeks

9.73±0.56

8.77±0.40

10.05±0.69

0.1555

 

Δ24weeks

–3.95±0.70

–5.57±0.50

–6.38±1.04

0.1349

 

Δ48weeks

–3.13±0.94

–5.16±0.55

–5.28±1.08

0.3454

Glycated hemoglobin (%)

Baseline

7.85±0.19

8.57±0.20

8.48±0.72

0.1006

 

24weeks

6.33±0.14

6.15±0.09

5.94±0.12

0.4329

 

48weeks

6.44±0.18

6.19±0.10

6.18±0.22

0.8843

 

Δ24weeks

–1.51±0.20

–2.42±0.19

–2.54±0.71

0.0096

 

Δ48weeks

–1.37±0.23

–2.35±0.22

–2.30±0.80

0.0101

Fasting insulin (mU/l)

Baseline

14.54±1.24

12.49±0.76

13.09±2.31

0.5310

 

24weeks

18.91±1.03

17.89±1.18

18.08±2.93

0.4065

 

48weeks

19.31±1.16

16.37±1.14

12.29±2.95

0.0212

 

Δ24weeks

4.36±0.99

5.37±1.10

4.99±3.84

0.9062

 

Δ48weeks

4.18±1.20

3.90±1.24

–0.80±2.83

0.2200

HOMA–IR

Baseline

5.67±0.43

5.28±0.32

5.52±1.08

0.8258

 

24weeks

5.69±0.38

5.07±0.33

5.33±0.78

0.2898

 

48weeks

6.10±0.44

4.94±0.36

3.78±0.92

0.0235

 

Δ24weeks

0.03±0.46

–0.26±0.38

–0.19±1.33

0.7546

 

Δ48weeks

0.35±0.47

–0.27±0.45

–1.74±1.11

0.0779

HOMA–B

Baseline

62.66±12.46

46.41±4.20

45.93±8.61

0.5175

 

24weeks

128.00±9.08

149.51±15.04

128.37±29.23

0.9195

 

48weeks

126.24±14.97

117.70±12.38

77.43±19

0.1525

 

Δ24weeks

63.70±12.32

103.08±14.16

82.43±30

0.5251

 

Δ48weeks

60.97±15.16

70.58±11.72

31.49±17.12

0.3893

Acute insulin response(mU/l)

Baseline

31.92±3.15

24.92±3.01

28.79±7.20

0.1084

 

24weeks

27.81±3.08

28.11±3.07

20.16±6.44

0.7199

 

48weeks

29.33±3.32

24.36±2.71

28.31±8.31

0.3450

 

Δ24weeks

–4.10±3.40

3.95±2.58

–8.63±5.93

0.0308

 

Δ48weeks

–3.31±4.36

–0.66±2.30

–0.47±7.69

0.9131

  1. Note: Data are shown as means ± SEM. P values <0.05 are shown in bold. Δ value = T24 or 48 weeks value - baseline (T0) value. P values were adjusted for age, gender and BMI at baseline when linear regression model was adopted.
  2. HOMA-B, homeostasis model assessment of β-cell function; HOMA-IR, homeostasis model assessment of insulin resistance.
Back to article page